Zeev Estrov, M.D.

Peer-Reviewed Articles

1. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
2. Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
3. Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 106(9):2384-2396, 2021. e-Pub 2021. PMID: 32732359.
4. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
5. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
6. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 133(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
7. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol 185(2):382-386, 2019. e-Pub 2018. PMID: 30074241.
8. Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
9. Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 variant hairy cell leukemia and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol 93(12):1568-1569, 2018. e-Pub 2018. PMID: 30152528.
10. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59(11):1-6, 2018. e-Pub 2018. PMID: 29465264.
11. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
12. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
13. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
14. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
15. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
16. Rozovski U, Keating MJ, Estrov Z. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?. Acta Haematol 140(1):51-54, 2018. e-Pub 2018. PMID: 30114695.
17. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
18. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
19. Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov Z. A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. Blood Res 52(1):71-73, 2017. e-Pub 2017. PMID: 28401108.
20. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
21. Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov Z. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica 102(1):79-84, 2017. e-Pub 2016. PMID: 27686378.
22. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2018. PMID: 29379494.
23. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
24. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723-40, 2016. e-Pub 2016. PMID: 27481130.
25. Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z. Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. J Vis Exp(112), 2016. e-Pub 2016. PMID: 27341356.
26. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma 57(5):1-19, 2016. e-Pub 2015. PMID: 26402369.
27. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 196(10):4400-9, 2016. e-Pub 2016. PMID: 27076684.
28. Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver N, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol 91(3):354-5, 2016. e-Pub 2016. PMID: 26437693.
29. Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z. Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma 57(4):1-8, 2016. e-Pub 2015. PMID: 26643954.
30. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
31. Kurzrock R, Estrov Z, Talpaz M, Kantarjian HM. Meir Wetzler, MD. Cancer 121(13):2106-7, 2015. e-Pub 2015. PMID: 25832851.
32. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z. Incidence of and risk factors for acute myeloid leukemia involvement of the central nervous system. Leuk Lymphoma 56(5):1-19, 2015. e-Pub 2014. PMID: 25110819.
33. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol 169(4):595-7, 2015. e-Pub 2014. PMID: 25413673.
34. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
35. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
36. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma 56(4):1-17, 2015. e-Pub 2014. PMID: 25048874.
37. Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: Current status and future perspectives. Cancer Lett 352(1):4-14, 2014. e-Pub 2013. PMID: 23879961.
38. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Mol Cancer Res 12(9):1267-82, 2014. e-Pub 2014. PMID: 24836891.
39. Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov Z. Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med 3(3):550-4, 2014. e-Pub 2014. PMID: 24678068.
40. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
41. Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia (CLL) with polyglandular autoimmune endocrinopathy (PGA) type II - a complex profile. Leuk Lymphoma 55(4):944-6, 2014. e-Pub 2014. PMID: 23829280.
42. Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123(9):1424-6, 2014. PMID: 24578497.
43. Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 88(3):655-66, 2013. e-Pub 2013. PMID: 23941728.
44. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma 54(11):2537-9, 2013. e-Pub 2013. PMID: 23343175.
45. Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov Z. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 54(11):2540-2, 2013. e-Pub 2013. PMID: 23387894.
46. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor?. Int J Cancer 133(3):534-43, 2013. e-Pub 2013. PMID: 23280377.
47. Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma 54(7):1364-6, 2013. e-Pub 2013. PMID: 23270583.
48. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Clin Lymphoma Myeloma Leuk 13(3):292-5, 2013. e-Pub 2012. PMID: 23265768.
49. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12(1):50, 2013. e-Pub 2013. PMID: 23725032.
50. Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov Z. Signal transducer and activator of transcription-3 induces MicroRNA-155 expression in chronic lymphocytic leukemia. PLoS One 8(6):e64678, 2013. e-Pub 2013. PMID: 23750211.
51. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 2012. e-Pub 2012. PMID: 22718840.
52. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome-positive acute lymphoblastic cells. Invest New Drugs 29(6):1206-12, 2011. e-Pub 2010. PMID: 20533075.
53. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 2011. e-Pub 2011. PMID: 21733558.
54. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs 29(5):1094-7, 2011. e-Pub 2010. PMID: 20517635.
55. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone Marrow Stroma Secreted Cytokines Protect JAK2V617F-Mutated Cells From The Effects Of A JAK2 Inhibitor. Cancer Res 71(11):3831-40, 2011. e-Pub 2011. PMID: 21512135.
56. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. J Clin Oncol 29(18):2507-13, 2011. e-Pub 2011. PMID: 21555694.
57. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 Activates NF-{kappa}B in Chronic Lymphocytic Leukemia Cells. Mol Cancer Res 9(4):507-15, 2011. e-Pub 2011. PMID: 21364020.
58. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. Transformation of Human Mesenchymal Cells and Skin Fibroblasts into Hematopoietic Cells. PLoS One 6(6):e21250, 2011. e-Pub 2011. PMID: 21731684.
59. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 5(7):e11859, 2010. e-Pub 2010. PMID: 20686606.
60. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z.. Signal transducer and activator of transcription (Stat)-3 activated the receptor tyrosine kinase-like orphan receptor-1 gene in chronic lymphocytic leukemia. PLoS One 5(7):1-11, 2010.
61. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115(14):2852-63, 2010. e-Pub 2010. PMID: 20154216.
62. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res 69(69):3910-17, 2009. e-Pub 2009. PMID: 19383925.
63. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7(3):464-73, 2008. PMID: 18347134.
64. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, A novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14(3):788-96, 2008. PMID: 18245540.
65. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291-9, 2007. PMID: 18056455.
66. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 31(1):91-5, 2007. e-Pub 2006. PMID: 16828865.
67. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6(8):671-9, 2006. PMID: 17168672.
68. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46(10):1795-802, 2006. PMID: 17002637.
69. Lev EI, Estrov Z, Aboulfatova K, Harris D, Granada JF, Alviar C, Kleiman NS, Dong JF. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost 96(4):498-504, 2006. PMID: 17003929.
70. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma 47(10):2049-54, 2006. PMID: 17071475.
71. Kurzrock R, Talpaz M, Li L, Estrov Z. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leuk Lymphoma 47(8):1651-64, 2006. PMID: 16966279.
72. Medeiros LJ, Estrov Z, Rassidakis GZ. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res 30(4):497-01, 2006. e-Pub 2005. PMID: 16203034.
73. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 12(2):340-4, 2006. PMID: 16428470.
74. Lev EI, Kleiman NS, Birnbaum Y, Harris D, Korbling M, Estrov Z. Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res 42(5):408-14, 2005. e-Pub 2005. PMID: 16088214.
75. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 2005. PMID: 15970928.
76. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 25(3B):1841-50, 2005. PMID: 16158916.
77. Freireich EJ, Kurzrock R, Estrov Z. Metastasis--an alternative hypothesis. Cancer 103(8):1537-9, 2005. PMID: 15739196.
78. Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology 9(4):279-86, 2004. PMID: 15621735.
79. Faderl S, Estrov Z. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma 45(1):67-71, 2004. PMID: 15061199.
80. Yeh ET, Zhang S, Wu HD, Körbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108(17):2070-3, 2003. e-Pub 2003. PMID: 14568894.
81. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102(3):987-95, 2003. e-Pub 2003. PMID: 12689943.
82. Kørbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept?. N Engl J Med 349(6):570-82, 2003. PMID: 12904523.
83. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102(2):630-7, 2003. e-Pub 2003. PMID: 12663443.
84. Faderl S, Estrov Z. Commentary: effect of flavonoids on normal and leukemic cells. Leuk Res 27(6):471-3, 2003. PMID: 12648504.
85. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-hydroxyphenyl) retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 27(3):259-266, 2003. PMID: 12537979.
86. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res 9(2):535-50, 2003. PMID: 12576416.
87. Torchilin V., Lakoubov L., Estrov Z.. Therapeutic potential of antinuclear autoantibodies in cancer. Cancer Ther 1:179-90, 2003.
88. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol 117(4):869-74, 2002. PMID: 12060122.
89. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99(9):3461-4, 2002. PMID: 11964319.
90. Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 346(10):738-46, 2002. PMID: 11882729.
91. Estrov Z, Huh YO, Ginsberg CF, Harris D, Van Q, Mirza NQ, Talpaz M, Korbling M. Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors. J Clin Apher 17(1):7-16, 2002. PMID: 11948700.
92. Faderl S, Estrov Z. Shift of immunoglobulin phenotypes in B-cell precursor cell lines. Leuk Res 26(1):11-2, 2002. PMID: 11734298.
93. Ravandi F, Talpaz M, Kantarjian H, Estrov Z. Cellular signalling pathways: new targets in leukemia therapy. Br J Haematol 116(1):57-77, 2002. PMID: 11841398.
94. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 2001. PMID: 11911247.
95. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol 22(8):424-7, 2001. PMID: 11473830.
96. Faderl S, Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma 40(5-6):471-481, 2001. PMID: 11426520.
97. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of minimal residual disease in leukemia. Int J Oncol 17(6):1277-87, 2000. PMID: 11078816.
98. Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol 23(2):213-5, 2000. PMID: 10776987.
99. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36(3-4):263-73, 2000. PMID: 10674898.
100. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94(8):2844-53, 1999. PMID: 10515888.
101. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther 5(3):159-63, 1999. PMID: 10641574.
102. Mavligit GM, Estrov Z, Ayala A. Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol 22(3):320-2, 1999. PMID: 10362346.
103. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?. Blood 93(9):2755-9, 1999. PMID: 10216068.
104. Estrov Z, Freedman MH. Detection of residual disease in acute lymphoblastic leukemia of childhood. Leuk Lymphoma 33(1-2):47-52, 1999. PMID: 10194120.
105. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res 5(12):4041-7, 1999. PMID: 10632337.
106. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92(9):3090-7, 1998. PMID: 9787143.
107. Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol 161(9):4702-8, 1998. PMID: 9794400.
108. Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma 30(5-6):583-9, 1998. PMID: 9711920.
109. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma 30(3-4):279-92, 1998. PMID: 9713960.
110. Faderl S, Estrov Z. Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther 4(2):73-85, 1998. PMID: 9681246.
111. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91(11):3995-4019, 1998. PMID: 9596644.
112. Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res 22(4):341-53, 1998. PMID: 9669839.
113. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16(4):1526-31, 1998. PMID: 9552062.
114. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48(2):165-74, 1998. PMID: 9596488.
115. Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M. Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med 131(3):261-8, 1998. PMID: 9523851.
116. Kurzrock R, Talpaz M, Beran M, Harris D, Estrov Z. DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia 12(2):242-6, 1998. PMID: 9519789.
117. Estrov Z, Roberts WM, Zipf TF.. Residual disease in acute lymphoblastic leukemia of childhood: Detection, quantitation, characterization and clinical significance. Int. J. Pediatr. Hematol. Oncol 5:251-66, 1998.
118. Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M, Estrov Z. 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest 100(7):1716-24, 1997. PMID: 9312169.
119. Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov Z. Physiology and pathophysiology of dendritic cells. Hum Pathol 28(5):563-79, 1997. PMID: 9158705.
120. McClain K, Estrov Z, Raju U, Kelley PK, Aggarwal BB. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes. Methods 11(1):83-7, 1997. PMID: 8990093.
121. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336(5):317-23, 1997. PMID: 9011783.
122. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 88(10):3987-97, 1996. PMID: 8916965.
123. Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia 10(9):1534-43, 1996. PMID: 8751477.
124. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer 66(4):515-9, 1996. PMID: 8635867.
125. Sarris AH, Talpaz M, Deisseroth AB, Estrov Z. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. Leukemia 10(5):757-65, 1996. PMID: 8656668.
126. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol 166(3):618-30, 1996. PMID: 8600166.
127. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma 20(3-4):181-97, 1996. PMID: 8624456.
128. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Detection of minimal residual disease in ALL: biology, methods, and applications. Cancer Treat Res 84:149-66, 1996. PMID: 8724630.
129. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 86(12):4594-602, 1995. PMID: 8541550.
130. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res 15(10):905-13, 1995. PMID: 8564713.
131. Estrov Z, Talpaz M, Estey EH, Strassmann G. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation. Exp Hematol 23(10):1080-7, 1995. PMID: 7544738.
132. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 98(6):551-8, 1995. PMID: 7539977.
133. Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther 1(1):65-9, 1995. PMID: 9384665.
134. Estrov Z, Kurzrock R, Talpaz M. Interleukin-1 and its inhibitors: implications for disease biology and therapy. Cancer Treat Res 80:51-82, 1995. PMID: 8821574.
135. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. . Leuk Lymphoma 16(1-2):79-88, 1994. PMID: 7535143.
136. Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z. Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells 12(6):638-49, 1994. PMID: 7533582.
137. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94(4):1383-9, 1994. PMID: 7929813.
138. Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov Z. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia 8(5):798-805, 1994. PMID: 8182937.
139. Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. Cancer Res 54(7):1837-42, 1994. PMID: 8137298.
140. Estrov Z, Ouspenskaia MV, Zipf TF, Tubergen DG, Roberts WM. Minimal residual leukaemia. Lancet 343(8901):858-9, 1994. PMID: 7908106.
141. Estrov Z, O'Brien S, Horvath A, Freedman MH.. Interruption of autocrine/paracrine growth factor stimulatory mechanisms: A potential approach for juvenile chronic myelogenous leukemia therapy. Int. J. Pediatr. Hematol. Oncol 1:253-8, 1994.
142. Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee MS, Harris D, Pinkel DP, Zipf TF. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 8(1):46-52, 1994. PMID: 8289497.
143. Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov Z. Growth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol 67(6):277-84, 1993. PMID: 7506581.
144. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med 234(4):417-20, 1993. PMID: 7691980.
145. McClain K, Estrov Z, Chen H, Mahoney DH. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol 85(1):57-62, 1993. PMID: 8251410.
146. Estrov Z, Re GG, Zipf TF. Immature and differentiated neoplastic populations in acute lymphocytic leukemia of childhood: Biological and clinical implications. Leuk Lymphoma 11(11):1-7, 1993. PMID: 8220141.
147. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res 53(14):3289-93, 1993. PMID: 8324740.
148. Estrov Z. Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia. Semin Hematol 30(3 Suppl 3):35-6, 1993. PMID: 7694373.
149. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med 177(3):763-74, 1993. PMID: 8382256.
150. Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells 11(2):112-9, 1993. PMID: 8384506.
151. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia 7(2):214-20, 1993. PMID: 8426475.
152. Estrov Z, Kurzrock, R Talpaz M.. Interruption of endogenous growth regulatory networks: A novel approach to inhibition of leukemia cell proliferation. FORUM Trends Exp. Clin. Med 3:306-18, 1993.
153. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk Lymphoma 11 Suppl 1:47-50, 1993. PMID: 8251916.
154. Zadik Z, Estrov Z, Karov Y, Hahn T, Barak Y. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report. J Pediatr Endocrinol 6(1):79-83, 1993. PMID: 8374694.
155. Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU. The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. Exp Hematol 20(7):886-90, 1992. PMID: 1628706.
156. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol 20(5):558-64, 1992. PMID: 1587302.
157. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79(8):1938-45, 1992. PMID: 1373331.
158. Freedman MH, Cohen A, Grunberger T, Bunin N, Luddy RE, Saunders EF, Shahidi N, Lau A, Estrov Z. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol 80(1):40-8, 1992. PMID: 1311195.
159. Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol 63(6):297-301, 1991. PMID: 1756190.
160. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 78(6):1476-84, 1991. PMID: 1715791.
161. Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz M. LIF: not just a leukemia inhibitory factor. Endocr Rev 12(3):208-17, 1991. PMID: 1935819.
162. Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TF. Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood 78(3):575-80, 1991. PMID: 1713508.
163. Estrov Z, Freedman MH. Acute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation. Exp Hematol 19(3):221-5, 1991. PMID: 1995313.
164. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 9(3):394-9, 1991. PMID: 1999709.
165. Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU. Synergistic antiproleferative effect of interferon alpha and aziodothymidine (AZT) in chronic myelogenous leukemia. Leukemia 5(2):101-7, 1991. PMID: 2020193.
166. Kurzrock R, Estrov Z, Talpaz M, Gutterman JU. Cytokines in tumor therapy. Interleukin-3. Am J Clin Oncol 14 Suppl 1:S45-50, 1991. PMID: 2048564.
167. Estrov Z, Resnitzky, P.. Clinical utility of hematopoietic growth factors. Harefuah, Journal of the Israel Medical Association 118:111-17, 1990.
168. Freedman MH, Estrov Z. Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect. Am J Pediatr Hematol Oncol 12(2):225-30, 1990. PMID: 2378417.
169. Estrov Z, Resnitzky P. [Hematopoietic growth factors and their clinical application]. Harefuah 118(2):111-7, 1990. PMID: 1690162.
170. Estrov Z, Freedman MH. Recent advances in juvenile chronic myelogenous leukemia. Harefuah 117(10):538-541, 1989. PMID: 2676769.
171. Estrov Z, Berrebi A, Kusminsky G, Resnitzky P. Circulating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis. Acta Haematol 81(4):213-6, 1989. PMID: 2502895.
172. Halperin DS, Estrov Z, Freedman MH. Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood 73(5):1168-74, 1989. PMID: 2649168.
173. Estrov Z, Freedman MH.. Juvenile chronic myelogenous leukemia(JCML): In vitro characterization of the disease. First Annual Meeting of the Israel Society of Pediactric Hematology-Oncology, Jerusalem, 1988.
174. Estrov Z, Freedman MH. Growth requirements for human acute lymphoblastic leukemia cells: refinement of clonogenic assay. Cancer Res 48(20):5901-07, 1988. PMID: 3048651.
175. Estrov Z, Gelfand, EW, Freedman, MH.. Cytotoxicity in vitro of deferoxamine on human marrow hematopoietic progenitors. Toxicol. In Vitro 2:131-4, 1988.
176. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol 10(4):288-91, 1988. PMID: 3239704.
177. Estrov Z, Halperin DS, Coceani F, Freedman MH. Modulation of human marrow haematopoiesis by leucotrienes in vitro. Br J Haematol 69(3):321-7, 1988. PMID: 2841965.
178. Freedman MH, Estrov Z, Chan HS. Juvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol 10(3):261-7, 1988. PMID: 3052147.
179. Freedman MH, Estrov Z. Juvenile chronic myelogenous leukaemia and histiocytosis syndromes in children. Lancet 1(8535):754, 1987. PMID: 2882175.
180. Estrov Z, Lau AS, Williams BR, Freedman MH. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. Exp Hematol 15(2):127-32, 1987. PMID: 3102273.
181. Chan HS, Estrov Z, Weitzman SS, Freedman MH. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol 5(12):1960-7, 1987. PMID: 2445935.
182. Estrov Z, Dubé ID, Chan HS, Freedman MH. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. Blood 70(5):1466-9, 1987. PMID: 3478101.
183. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood 69(4):1161-6, 1987. PMID: 3103713.
184. Estrov Z, Tawa A, Wang XH, Dubé ID, Sulh H, Cohen A, Gelfand EW, Freedman MH. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69(3):757-61, 1987. PMID: 3493042.
185. Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia 1(5):437-41, 1987. PMID: 3312841.
186. Estrov Z, Grunberger T, Freedman MH. Clinical utility of marrow cell tissue cultures in acute leukemia of childhood. Am J Hematol 23(1):51-8, 1986. PMID: 3461711.
187. Estrov Z, Grunberger T, Dubé ID, Wang YP, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med 315(9):538-42, 1986. PMID: 3488505.
188. Estrov Z, Roifman C, Wang YP, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on early and mature erythroid progenitor proliferation. Blood 67(6):1607-10, 1986. PMID: 3486684.
189. Estrov Z, Grunberger T, Chan HS, Freedman MH. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood 67(5):1382-7, 1986. PMID: 3486010.
190. Estrov Z, Zimmerman B, Grunberger T, Chao J, Teshima IE, Chan HS, Freedman MH. Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia. Cancer Res 46(12 Pt 1):6456-61, 1986. PMID: 3465439.
191. Freedman MH, Estrov Z, Williams BR, Gelfand EW. Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2. Am J Pediatr Hematol Oncol 8(3):178-82, 1986. PMID: 3766908.
192. Kaplinsky C, Estrov Z, Freedman MH, Cohen A. Induction of differentiation in HL-60 promyelocytic cells: a comparative study in two sublines. Blood Cells 11(3):459-68, 1986. PMID: 3461855.
193. Nussinson E, Estrov Z, Vigder L, Zur N.. Midgut malrotation in adolescents and adults. The Family Physician 3:58-62, 1985.
194. Resnitzky P, Estrov Z, Haran-Ghera N. High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids. Leuk Res 9(12):1519-28, 1985. PMID: 3866124.
195. Wishnitzer R, Estrov Z, Caspi A, Eliraz A. [Pneumonitis due to amiodarone]. Harefuah 107(5-6):131-3, 1984. PMID: 6510818.
196. Estrov Z, Resnitzky P, Shenker Y, Berrebi A, Hurwitz N. Candidemia and sternal Candida albicans osteomyelitis in a patient with chronic lymphatic leukemia. Isr J Med Sci 20(8):711-4, 1984. PMID: 6469595.
197. Coslovsky R, Bruck R, Estrov Z. Hypo-osmolal syndrome due to prolonged nausea. Arch Intern Med 144(1):191-2, 1984. PMID: 6691759.
198. Estrov Z, Bruck R, Shtalrid M, Berrebi A, Resnitzky P. Histiocytic hemophagocytosis in Q fever. Arch Pathol Lab Med 108(1):7, 1984. PMID: 6546341.
199. Estrov Z, Resnitzky P. Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitory drugs. Exp Hematol 11(9):802-9, 1983. PMID: 6139289.
200. Berrebi A, Estrov Z, Chemke J. Chronic myeloid leukemia following radiotherapy for breast cancer. Isr J Med Sci 19(7):653-4, 1983. PMID: 6576990.
201. Bruck R, Estrov Z, Resnitzky P, Bar-Khayim Y. Recurrent anuria in severe hypercapnic acidosis. Isr J Med Sci 19(7):649-50, 1983. PMID: 6885351.
202. Estrov Z, Berrebi A, Nussinson E, Kohn D. [Sinus histiocytosis with massive lymphadenopathy]. Harefuah 104(9):387-9, 1983. PMID: 6674048.
203. Estrov Z, Berrebi A, Hazani E, Resnitzky P. Pleural effusion and ascites as presenting signs of IgA myeloma. Haematologica 68(1):104-9, 1983. PMID: 6404700.
204. Shenker Y, Estrov Z, Nussinson E, Landau Z, Resnitzky P. [Schistosomiasis mansoni infestation treated with oxamnaquine]. Harefuah 103(9):199-200, 1982. PMID: 7169187.
205. Landau, Estrov Z, Bruck, R. Auricular calcification - a forgotten sign of Addison's disease. Harefuah, Journal of the Israel Medical Association 103:224-225, 1982.
206. Berrebi A, Estrov Z, (Reehovot). Twenty years follow-up in a patient with multiple myeloma. Acta Haematol 66(4):269-70, 1981. PMID: 6800195.
207. Estrov Z, Kohn D, Sofer O, Schonfeld S. [Acute renal failure as a result of intravenous cholangiography (meglumine iodipamide)]. Harefuah 94(3-4):133-4, 1978. PMID: 658793.
208. Kohn D, Estrov Z, Schonfeld S.. Megaloblastic anemia in a vegan. Ind. Med. J 72:152-5, 1978.

Invited Articles

1. Stock, W, Estrov Z. Detection of minimal residual disease in acute lymphoblastic leukemia. UptoDate, 2012.
2. Estrov Z. Stem cells and somatic cells: reprogramming and plasticity. Clin Lymphoma Myeloma 9 Suppl 3:S319-28, 2009. PMID: 19778860.
3. Estrov Z.. Stem cells and somataic cells: reprogramming and plasticity. Clin Lymphoma Myeloma 9:S319-28, 2009.
4. Hennessy B, Körbling M, Estrov Z. Circulating stem cells and tissue repair. Panminerva Med 46(1):1-11, 2004. PMID: 15238877.
5. Korbling M, Estrov Z.. Adult stem cells for tissue repair. Preclinica 2:1-4, 2004.
6. Körbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant 32 Suppl. 1:S23-4, 2003. PMID: 12931235.
7. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 14(6):1289-305, 2000. PMID: 11147224.
8. Faderl S, Estrov Z.. Hematopoietic growth factors and cytokines. Clin. Ligand Assay 23:169-80, 2000.
9. Faderl S, Kurzrock R, Estrov Z. Minimal residual disease in hematologic disorders. Arch Pathol Lab Med 123(11):1030-4, 1999. PMID: 10539902.
10. Faderl S, Estrov Z.. Cytokines: Characterization and function. Diag. Endocrinol. Immunol. Metabol 17:107-23, 1999.
11. Faderl S, Estrov Z. The clinical significance of detection of residual disease in childhood ALL. Crit Rev Oncol Hematol 28(1):31-55, 1998. PMID: 9715769.
12. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Leuk Lymphoma 24(5-6):379-91, 1997. PMID: 9086432.
13. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in leukemia. Cytokines Mol Ther 2(1):1-11, 1996. PMID: 9384684.
14. Estrov Z, Talpaz M.. Potential therapeutic utility of interleukin-1B converting enzyme (ICE) inhibitors in leukemia. Drugs News Perspect 9:5-12, 1996.
15. Estrov Z, Kurzrock R, Talpaz M. Cytokines and their antagonists in myeloid disorders. Semin Hematol 32(3):220-31, 1995. PMID: 7570065.
16. Estrov Z, Kurzrock R, Talpaz M.. Growth factor inhibitory molecules: a novel therapy of leukemia. Interferons Cytokines 24:22-5, 1993.
17. Estrov Z. Interruption of autocrine and paracrine growth-stimulatory mechanisms: A novel therapeutic strategy for chronic myelogenous leukemia. Semin. Hematol 30 (Suppl. 3):35-6, 1993.

Book Chapters

1. Rozovski U, Estrov Z. The Leukemia Stem Cell. In: Role of Cancer Stem Cells in Cancer Biology and Therapy. 1. Taylor & Francis, 98-128, 2013.
2. Santos F, Hazan-Halevy I, Estrov Z. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy. In: Cell Signaling & Molecular Targets in Cancer. Springer: New York, NY USA, 299-321, 2012.
3. Estrov Z.. Genetics, Biology and Therapy of Acute Myelogenous Leukemia. In: The leukemia stem cell. Springer: New York, NY, USA, 1-17, 2010.
4. Estrov Z. The leukemia stem cell. Genetics, Biology and Therapy of Acute Myelogenous Leukemia. In: Cancer Treat Res, 1-17, 2010.
5. Ravandi F, Estrov Z.. Role of leukemia inhibitory factor in Cancer and Cancer Metastasis. In: Growth Factors and Their Receptors in Cancer Metastasis. Kluer Academic Publishers: Amsterdam, The Nederlands, 1-25, 2001.
6. Fayad L, Estrov Z.. Role of cytokines and adhesion molecules in chronic myelogenous leukemia. In: Medical Management of Chronic Myelogenous Leukemia. H.M. Marcel Dekker Inc: New York, 363-96, 1998.
7. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Detection of minimal residual disease in ALL: Biology, methods and applications. In: Molecular Genetics and Therapy of Leukemia. Springer: US, 149-166, 1996.
8. Estrov Z, Kurzrock R, Wetzler M, Talpaz M.. Hematopoietic stem, progenitor, and colony-forming cells: Fundamental in vitro hematopoietic models. In: Molecular Biology in Clinical Oncology and Hematology. Martin Dunitz Publishers: London, England, 38-53, 1995.
9. Estrov Z, Kurzrock R, Talpaz M.. Interkeukin-1 and its inhibitors: Implication for disease biology and therapy. In: Cytokines:Interleukins and their receptors. Kluger Academic Publishers: London, England, 51-82, 1995.
10. Estrov Z, Ferrajoli A, Wetzler M, Kurzrock R, Talpaz M.. Interruption of autocrine growth factor loops: A new approach in leukemia therapy. In: Challenges of Modern Medicine. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma. AresSerono Symposia Publications: Rome, Italy, 185-8, 1994.
11. Estrov Z, Kurzrock R, Wetzler M, Talpaz M.. Use of growth factor receptor inhibitors in human neoplasms. In: Hematopoietic Growth Factors, Oncogenes and Cytokines In Clinical Hematology: Current Aspects and Future Directions. R. Karger Medical and Scientific Publishers: Basel, Switzerland, 178-95, 1994.
12. Estrov Z, Kurzrock R, Talpaz M. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. In: Leuk Lymphoma. 6. Harwood Academic Publishers: Chur, Switzerland, 29-40, 1993.
13. Talpaz M, Estrov Z, Wetzler M, Kruzrock R.. Interferon action in myeloproliferative disorders: Mechanisms of response and resistance to therapy. In: Bilogic Response Modifiers in the Treatment of Hematopoietic Neoplasia. Marcel Dekker Inc: New York, 19-26, 1992.
14. Estrov Z, Talpaz M, Wetzler M, Kurzrock R. The modulatory hematopoietic activities of leukemia inhibitory factor. In: Leuk Lymphoma. 8. Pollack A. Harwood Academic Publishers: Chur, Switzerland, 1-7, 1992.

Books (edited and written)

1. Estrov Z, Kurzrock R, Talpaz M.. Interferons: basic principles and clinical applications. R.G. Landes Company: Austin, 1993.

Letters to the Editor

1. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction Between Myelomonocytic and Lymphoid Cells in a Patient with Acute MyeloMonocytic Leukemia and Chronic Lymphocytic Leukemia. Leuk Lymphoma 55: 1425-7, 2014.
2. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system (CNS) Richter's transformation and parvovirus B19 infection. Leuk Lymphoma 54: 2070-2, 2013.
3. Hazen-Halevy I, Harris D, liu Z, Li P, Estrov Z.. Lentiviral vectors and transduction of human cancer B cells. Blood: 500, 2010.
4. Korbling M, Estrov Z.. Male cells in female recipients of hematopoietic-cell transplants. N. Engl. J. Med 347: 219-20, 2002.
5. Faderl S, Estrov Z. Detection of residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 340: 152-3, 1999.
6. Faderl S, Talpaz M, Kantarjian HM, Estrov Z.. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood 94: 1484-8, 1999.
7. Faderl S, Talpaz M, Kantarjian HM, Estrov Z.. Polymerase chain reaction analyses should be used as basis for clinical decision making in patients with CML. Blood 94: 3609-11, 1999.
8. Reading CL, Juttner C, Gazitt Y, Estrov Z.. Does CD34+ cell selection enrich for malignant stem cells in B-cells (and other) malignancies?. J. Hematother 5: 97-8, 1996.
9. Roberts WM, Estrov Z, Zipf TF. Detection of minimal residual disease in acute lymphoblastic leukemia. Blood 86: 1237-9, 1995.
10. Estrov Z, Ouspenskaia MV, Zipf TF, Tubergen DG, Roberts MR. Minimal residual leukemia. Lancet 343: 858-9, 1994.
11. Freedman MH, Estrov Z. Clonal origin of erythroid cells in juvenile chronic myelogenous leukemia. Blood 69: 976, 1987.
12. Freedman MH, Estrov Z. Juvenile chronic myelogenous leukemia and histiocytosis syndromes in children. Lancet 1: 754, 1987.
13. Kohn D, Estrov Z. Intravascular coagulation and hepatic injury. Ann. Intern. Med 88: 130, 1978.